Spyre Therapeutics Overview
Latest ROE for Spyre Therapeutics: -16.25% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-16.25%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for SYRE is -16.25%. That is below the Healthcare sector average of 22.76%. Investors often review this figure alongside Spyre Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, SYRE currently prints -16.25% for ROE, while the sector average sits near 22.76%. That is roughly 171.4% below the sector mean. Large gaps often invite a closer look at Spyre Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Spyre Therapeutics converts resources into returns. At -16.25%, SYRE may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting SYRE's ROE (-16.25%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Spyre Therapeutics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
